Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 6:18:1619-1627.
doi: 10.2147/NDT.S368740. eCollection 2022.

Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study

Xuexue Bai  1 , Xiaomin Liu  2 , Jun Wen  1
Affiliations

Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study

Xuexue Bai et al. Neuropsychiatr Dis Treat. .

Abstract

Objective: We investigated the role of bevacizumab (BV) in high-grade meningiomas (HGMs) by retrospective analysis.

Methods: We retrospectively analyzed the clinical data of 139 patients with HGMs. The chi-square test was used to compare progression-free survival (PFS) and overall survival (OS) between patients who received BV and those who did not. According to whether they received BV treatment, we divided the patients into the BV group and non-BV group, and the effect of BV on PFS and OS was compared. In addition, we compared Karnofsky performance status (KPS) and steroid doses between the BV and non-BV groups.

Results: There were statistically differences in PFS and OS between the BV and non-BV groups at 12 and 36 months after surgery (P<0.05). However, there was no significant difference in PFS and OS between the two groups at 60 months postoperatively (P>0.05). Using survival curves drawn by the Kaplan Meier method, we found that the PFS and OS of the BV group were greater than those of the non-BV group, and the difference was statistically significant (P<0.05).

Conclusion: BV could improve PFS and OS at 12 and 36 months after surgery in patients with HGMs. In addition, BV was associated with lower preoperative steroid use.

Keywords: bevacizumab; meningiomas; overall survival; peritumoral brain edema; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Figure 1
Figure 1
Imaging and pathological results of High-grade meningioma. (A) Preoperative imaging examination of WHO II meningioma. (B) Postoperative imaging examination of WHO II meningioma. (C) Postoperative pathological results of WHO II meningioma. (D) Preoperative imaging examination of WHO III meningioma. (E) Postoperative imaging examination of WHO III meningioma. (F) Postoperative pathological results of WHO III meningioma.
Figure 2
Figure 2
Survival curves drawn by the Kaplan Meier method. (A) Progression-free survival curves of the bevacizumab group and the non-bevacizumab group. (B) Overall survival curves of the bevacizumab group and the non-bevacizumab group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682–694. doi:10.1016/S1470-2045(17)30155-9 - DOI - PubMed
    1. Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 2000;38(1):45–52. doi:10.1016/S0920-1211(99)00066-2 - DOI - PubMed
    1. Vignes JR, Sesay M, Rezajooi K, et al. Peritumoral edema and prognosis in intracranial meningioma surgery. J Clin Neurosci. 2008;15(7):764–768. doi:10.1016/j.jocn.2007.06.001 - DOI - PubMed
    1. Sindou MP, Alaywan M. Most intracranial meningiomas are not cleavable tumors: anatomic-surgical evidence and angiographic predictibility. Neurosurgery. 1998;42(3):476–480. doi:10.1097/00006123-199803000-00007 - DOI - PubMed

LinkOut - more resources